Therapeutic Asset Ratings
1,045 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Trastuzumab Emtansine
Breast Inflammatory Carcinoma
Hoffmann-La Roche
P3
BB
(67)
Brentuximab Vedotin
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
M.D. Anderson Cancer Center
P2
BB
(67)
rc48-adc
Advanced Gastroesophageal Junction Adenocarcinoma
BeOne Medicines
P2
BB
(67)
Tisotumab Vedotin
Carcinoma, Squamous Cell of Head and Neck
Seagen, a wholly owned subsidiary of Pfizer
P2
BB
(67)
rc48-adc
Small Cell Lung Cancer
BeOne Medicines
P4
BB
(66)
Trastuzumab Deruxtecan
Brain Metastases
Baptist Health South Florida
P4
BB
(66)
Trastuzumab Emtansine
HER2-positive Breast Cancer
SWOG Cancer Research Network
P4
BB
(66)
Brentuximab Vedotin
Adult Mixed Cellularity Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(66)
Brentuximab Vedotin
Adult Nodular Sclerosis Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(66)
Brentuximab Vedotin
Classical Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(66)
Brentuximab Vedotin
Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(66)
Brentuximab Vedotin
Lymphocyte-Rich Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(66)
Inotuzumab Ozogamicin
B Lymphoblastic Lymphoma
Alliance for Clinical Trials in Oncology
P3
BB
(66)
rc48-adc
Gastric Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
P3
BB
(66)
Trastuzumab Emtansine
Breast Cancer
SWOG Cancer Research Network
P3
BB
(66)
Trastuzumab Emtansine
Stage IV Breast Cancer
SWOG Cancer Research Network
P3
BB
(66)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter
National Cancer Institute (NCI)
P2
BB
(66)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Stage IIIB Bladder Cancer AJCC v8
Fred Hutchinson Cancer Center
P2
BB
(66)
Gemtuzumab Ozogamicin
Recurrent Adult Acute Myeloid Leukemia
Medical College of Wisconsin
P2
BB
(66)
Trastuzumab Deruxtecan
Colon Cancer Metastatic
M.D. Anderson Cancer Center
P2
BB
(66)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Advanced or Metastatic Solid Malignancies
National Cancer Institute (NCI)
P2/3
BB
(66)
Datopotamab Deruxtecan
Stomatitis
AstraZeneca
P4
BB
(65)
rc48-adc
Neoadjuvant Therapy
First Affiliated Hospital of Guangxi Medical University
P4
BB
(65)
Brentuximab Vedotin
Lymphoma, Non-Hodgkin
New York Medical College
P3
BB
(65)
Polatuzumab Vedotin
Non-Hodgkin Lymphoma
Genmab
P3
BB
(65)
Showing 26 to 50 of 1,045 assets
Previous
Page 2 of 42
Next